289 results on '"Pecen, Ladislav"'
Search Results
2. Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry
3. Role of risk factors, scoring systems, and prognostic models in predicting the functional outcome in meningioma surgery: multicentric study of 552 skull base meningiomas
4. Long-term outcome of Simpson IV meningioma resection: Would it improve with adjuvant SRS?
5. Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy.
6. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
7. Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
8. Comparison of four routinely used vitamin D automated immunoassays
9. Twinning for the Armenian research infrastructure on cancer research
10. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia ― One-Year Data From the Global ETNA-AF Program ―
11. Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions
12. Deficient mismatch repair as a prognostic marker in stage II colon cancer patients
13. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation
14. Preanalytical stability of molecular forms of prostate-specific antigen in serum samples (PSA, free PSA, [-2]proPSA) and their impact on fPSA/tPSA ratio and PHI.
15. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries
16. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy
17. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy
18. Role of gamma knife radiosurgery in the treatment of prolactinomas
19. Blood biomarker panel recommended for personalized prediction, prognosis, and prevention of complications associated with abdominal aortic aneurysm
20. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry
21. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
22. Supplementary Data from TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer
23. Vitamin D3 Supplementation: Comparison of 1000 IU and 2000 IU Dose in Healthy Individuals
24. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program
25. Assessment of Prostate Carcinoma Aggressiveness: Relation to68Ga-PSMA-11-PET/MRI and Gleason Score
26. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients
27. EPMA-World Congress 2015: Bonn, Germany. 3-5 September 2015
28. Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry
29. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
30. Czech Inflammatory Cardiomyopathy Immunosuppression Trial (CZECH-ICIT): Randomized, multicentric study comparing the effect of two regimens of combined immunosuppressive therapy in the treatment of inflammatory cardiomyopathy: The aims and design of the trial
31. Gamma knife radiosurgery for Cushing’s disease and Nelson’s syndrome
32. Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis
33. Vitamin D 3 Supplementation: Comparison of 1000 IU and 2000 IU Dose in Healthy Individuals.
34. Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection
35. The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors
36. Could the new coronavirus have infected humans prior November 2019?
37. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
38. Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
39. Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries
40. Computed tomography with a full FOV photon-counting detector in a clinical setting, the first experience
41. Breast cancer risk assessment in the Czech female population – an adjustment of the original Gail model
42. Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test
43. Could Italy host the new coronavirus before China?
44. The Usefulness of Tumor Markers in Patients with Colorectal Carcinoma for the Detection of Local Recurrences and Distant Metastases
45. Distribution-insensitive cluster analysis in SAS on real-time PCR gene expression data of steadily expressed genes
46. Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies
47. Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
48. M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
49. Biomarkers in Combination with Other Prognostic and Predictive Factors –Individualized Multivariate Statistical Models for Risk and Probability Estimation in Oncology.Implementation into software BIANTA and CRACTES with Some Casuistics
50. Epidemiological and Microbiological Aspects of the Peritonsillar Abscess
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.